BUZZ-Viatris rises as FDA begins review of eye drop for age‑related near‑vision loss** Shares of generic drugmaker Viatris VTRS.O rise 1.5% to $16.31 premarket
** Co says FDA accepted its application to expand Ryzumvi’s use for the treatment of presbyopia, an age‑related condition that makes it harder to see things up close
** Presbyopia affects most people over 45; causes blurred near vision and eye strain
** Co says filing is backed by two late‑stage studies showing improved near vision with no serious side effects
** FDA decision expected by October 17, 2026, per co
** Shares down ~27% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments